← Back to headlines
Tenax Therapeutics Identifies Subgroup Benefit Despite Overall Phase 3 Trial Miss
Clinical trial data revealed that Tenax's experimental treatment showed therapeutic benefits for a sicker patient subgroup, even though the primary endpoint of the Phase 3 study was missed.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
